Oxford Biomedica (OXB) is one of few global lentiviral vector manufacturers with capacity in a thriving cell and gene therapy industry, and its FY20 results highlight strong operational progress throughout the business. OXB boasts a diversified revenue base; and FY20 benefited from new deals including Juno/BMS covering multiple CAR-T programmes, as well as increased bioprocessing and commercial development activities for several customers including Novartis and the AZN COVID-19 vaccine. Post per ....
27 May 2021
Oxford Biomedica - Driving innovation in a thriving CGT industry
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Oxford Biomedica - Driving innovation in a thriving CGT industry
Oxford BioMedica plc (OXB:LON) | 202 -4.1 (-1.0%) | Mkt Cap: 202.5m
- Published:
27 May 2021 -
Author:
Dr Susie Jana -
Pages:
11
Oxford Biomedica (OXB) is one of few global lentiviral vector manufacturers with capacity in a thriving cell and gene therapy industry, and its FY20 results highlight strong operational progress throughout the business. OXB boasts a diversified revenue base; and FY20 benefited from new deals including Juno/BMS covering multiple CAR-T programmes, as well as increased bioprocessing and commercial development activities for several customers including Novartis and the AZN COVID-19 vaccine. Post per ....